Potent Ophthalmic Corticosteroid — Uveitis / Post-Operative Inflammation Pregnancy: Use with caution — negligible systemic absorption; topical steroids generally avoided in first trimester; specialist advice required

Difluprednate 0.05% Eye Drops

Brand names: Durezol

Adult dose

Dose: Anterior uveitis: 1 drop four times daily; severe inflammation: 1 drop eight times daily initially; Post-op inflammation: 1 drop four times daily for 2 weeks then taper

Route: Topical ophthalmic emulsion

Frequency: Four to eight times daily depending on severity

Max: 1 drop eight times daily (acute severe inflammation)

Difluprednate is a potent steroid (more anti-inflammatory than prednisolone acetate 1%); taper slowly to avoid rebound inflammation; IOP monitoring mandatory — high steroid responder risk; FDA approved 2008; used off-label in UK

Paediatric dose

Route: Topical

Frequency: As directed by specialist

Max: 1 drop four times daily

Used by paediatric ophthalmologists for JIA-associated uveitis — specialist use only; IOP monitoring especially important in children who may not report symptoms

Dose adjustments

Renal

No adjustment required (negligible systemic absorption)

Hepatic

No adjustment required

Clinical pearls

Potency: difluprednate 0.05% has greater anti-inflammatory potency than prednisolone acetate 1% — the difluoroprednisolone structure and acetate ester at C17 enhance corticosteroid receptor affinity; useful for severe anterior uveitis where prednisolone drops have failed or for rapidly progressive uveitis requiring aggressive early treatment
Anterior uveitis treatment: first-line intense steroid for acute severe anterior uveitis — QDS to Q1-2H during first 48 hours; successful treatment reduces risk of posterior synechiae formation, band keratopathy, and secondary glaucoma; taper guided by inflammatory cell and flare reduction on slit-lamp
IOP risk is highest among topical steroids: difluprednate has the greatest IOP elevation profile — all patients require IOP monitoring every 1–2 weeks during acute treatment; steroid responders (IOP >21 mmHg on steroids) occur in ~30–40%; may require concurrent IOP-lowering drops (timolol, dorzolamide)
JIA-associated uveitis: juvenile idiopathic arthritis is a leading cause of childhood uveitis — often asymptomatic white eye (unlike adult uveitis); difluprednate used under paediatric rheumatology/ophthalmology co-management for active inflammation; transitioning to methotrexate or biologics for long-term steroid sparing
Comparison with dexamethasone: difluprednate reaches higher intraocular drug levels than dexamethasone 0.1% — for very severe inflammation or steroid-resistant cases; however, the higher potency also means greater IOP and cataract risk; use difluprednate for severe cases and deescalate to loteprednol or prednisolone as inflammation resolves

Contraindications

Active viral ocular infection (herpes simplex keratitis)
Fungal ocular disease
Mycobacterial ocular infection
Untreated bacterial infection
Hypersensitivity to difluprednate

Side effects

IOP elevation (significant risk — most potent IOP elevation among topical steroids)
Posterior subcapsular cataract
Mydriasis
Ptosis
Delayed wound healing
Secondary infection risk
Corneal thinning with prolonged use

Interactions

Other IOP-lowering agents — may be needed concurrently to control steroid-induced IOP elevation
Other topical preparations — administer 5 minutes apart

Monitoring

IOP every 1–2 weeks during treatment
Slit-lamp anterior chamber cells and flare
Posterior subcapsular lens changes
Corneal epithelial integrity
Intraocular pressure response to treatment

Reference: BNFc; BNF 90; FDA Approval Durezol 2008; SPC Difluprednate 0.05%; Sheppard et al. Trans Am Ophthalmol Soc 2014; RCOphth Uveitis Management Guidelines. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways